Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma
- 28 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 25 (7), 1334-1345
- https://doi.org/10.1007/s10147-020-01675-0
Abstract
Background Epithelium-specific ETS 3 (ESE3) is down-regulated frequently in several malignancies and involved in carcinogenesis and progression. However, ESE3 expression pattern and its relationship with clinical features and prognosis in hepatocellular carcinoma (HCC) are still largely unknown. Methods ESE3 expression was analyzed by quantitative real-time PCR and western blotting in HCC cell lines, and then, it was analyzed by immunohistochemistry in HCC tissues and peritumoral normal tissues from total 94 HCC patients. The relationship between ESE3 expression and clinical features was investigated to illustrate the potential prognostic value in HCC. ESE3 roles on HCC progression were evaluated in vitro and vivo by MTT assay and mice tumor model, respectively. Results ESE3, mainly located in the cytoplasm, was remarkably down-regulated in HCC tissues and cell lines. Low ESE3 expression was positively associated with tumor progression and metastasis features. Kaplan–Meier analysis demonstrated that low ESE3 expression contributed to poor recurrence-free survival (RFS) and overall survival (OS) (both p < 0.01) of patients, and maintained its prognostic value in predicting poor RFS and OS of “Early-stage” HCC patients regardless of clinical features being studied. Multivariate survival analysis was also identified ESE3 as an independent prognostic factor for RFS (p = 0.05 for marginal significance) and OS (p = 0.031). ESE3 expression restoration in cells led to a significant inhibition in HepG2 cell proliferation in vitro and vivo (both p < 0.001). Conclusions Down-regulated ESE3 expression in HCC tissues could serve as a potential therapeutic target against HCC and appears to be as a poor prognostic indicator for prognosis, especially in “Early-stage” HCC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81602550, 81871700)
- Science and Technology Development Project of Shandong Province (2018GSF118072)
- Natural Science Foundation of Shandong Province (ZR2018BH003)
This publication has 23 references indexed in Scilit:
- ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and CancerMolecules, 2018
- Hepatocellular carcinomaThe Lancet, 2018
- Biomarkers in hepatocellular carcinoma: an overviewExpert Review of Gastroenterology & Hepatology, 2017
- ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-CadherinCancer Research, 2017
- Anatomical resection of hepatocellular carcinoma: A critical review of the procedure and its benefits on survivalWorld Journal of Gastroenterology, 2017
- The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartmentOncotarget, 2016
- Molecular mechanisms of ETS transcription factor-mediated tumorigenesisCritical Reviews in Biochemistry and Molecular Biology, 2013
- ETS transcription factors and their emerging roles in human cancerEuropean Journal of Cancer, 2005
- Molecular biology of the Ets family of transcription factorsGene, 2003
- The ETS-domain transcription factor familyNature Reviews Molecular Cell Biology, 2001